RNS21 Nov 2017 10:56
The UK market represents approximately 20% of the Group's revenues, a proportion which is decreasing as the international customer base expands.
Dr Stephen Little, CEO, said, "we are very disappointed with this ruling and deeply disagree with the interpretation the Judge has given to precise technical language in the patents. The effect of the Judgment could potentially limit the access of UK patients to NIPT and, in certain respects, diverges from decisions made in other jurisdictions. We are seeking leave to appeal and continue to believe that the motivation behind these legal actions is competitive rather than technical. In the meantime we will continue to offer our high quality NIPT solutions and support to pregnant women and their clinicians in the UK, as we continue to expand our business into territories where we can operate with greater legal certainty. In addition we are accelerating plans to broaden the menu of tests we offer beyond NIPT and which should be cash generative in 2018. We will also focus on mitigating any financial implications of the litigation."
This will bounce back IMHO